XOMA Ltd. (NASDAQ: XOMA) announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE